EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Unveiling Metabolic Signatures as Potential Biomarkers in Common Cancers: Insights from Lung, Breast, Colorectal, Liver, and Gastric Tumours

Kha Wai Hon iD, Rakesh Naidu iD

Biomolecules · 28.09.2025 · 15 (10) · 1376

DOI: 10.3390/biom15101376 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biomolecules, online erschienen am 28.09.2025. Verfasst von Kha Wai Hon und 1 weiteren Autor:innen. Beteiligte Einrichtung: Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Jalan Lagoon Selatan, Bandar Sunway 47500, Selangor, Malaysia. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Breast Neoplasms, Lung Neoplasms, Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 333 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Reprogramming is a hallmark of cancer, enabling tumour cells to sustain rapid proliferation, resist cell death, and adapt to hostile microenvironments. This review explores the expression profiles of key metabolic enzymes and transporters involved in glucose, amino acid, and lipid metabolism across the five most deadly cancers worldwide: lung, breast, colorectal, liver, and gastric cancers. Through a comparative analysis, we identify consistent upregulation of glycolytic enzymes such as LDHA, PKM2, and HK2, as well as nutrient transporters like GLUT1, ASCT2, and LAT1, which contribute to cancer progression, metastasis, and therapy resistance. The role of enzymes involved in glutaminolysis (e.g., GLS1, GDH), one-carbon metabolism (e.g., SHMT2, PHGDH), and fatty acid synthesis (e.g., FASN, ACLY) is also examined, with emphasis on their emerging relevance as diagnostic, prognostic, and predictive biomarkers. While several metabolic proteins show strong potential for clinical translation, only a few, such as tumour M2-pyruvate kinase (TuM2-PK) and serum LDH measurement, have progressed into clinical use or trials. This review addresses some of the challenges in biomarker development. Ultimately, our findings underscore the importance of metabolic proteins not only as functional drivers of malignancy but also as promising candidates for biomarker discovery. Advancing their clinical implementation could significantly enhance early detection, treatment stratification, and personalized oncology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biomarkers, TumorBreast NeoplasmsLung NeoplasmsNeoplasmsHumansColorectal NeoplasmsStomach NeoplasmsLiver NeoplasmsFemale

Stichwörter der Autor:innen

biomarkerbreast cancercolorectal cancergastric cancerliver cancerlung cancermetabolic proteins

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Jalan Lagoon Selatan, Bandar Sunway 47500, Selangor, Malaysia.

ORCID-Profile: Kha Wai Hon, Rakesh Naidu

Zitieren

APA

Hon, K. W., & Naidu, R. (2025). Unveiling Metabolic Signatures as Potential Biomarkers in Common Cancers: Insights from Lung, Breast, Colorectal, Liver, and Gastric Tumours. Biomolecules, 15(10), 1376. https://doi.org/10.3390/biom15101376

Vancouver

Hon KW, Naidu R. Unveiling Metabolic Signatures as Potential Biomarkers in Common Cancers: Insights from Lung, Breast, Colorectal, Liver, and Gastric Tumours. Biomolecules. 2025;15(10):1376. doi:10.3390/biom15101376

BibTeX
@article{Hon2025,
  author = {Hon, Kha Wai and Naidu, Rakesh},
  title = {Unveiling Metabolic Signatures as Potential Biomarkers in Common Cancers: Insights from Lung, Breast, Colorectal, Liver, and Gastric Tumours},
  journal = {Biomolecules},
  year = {2025},
  volume = {15},
  number = {10},
  pages = {1376},
  doi = {10.3390/biom15101376}
}
Kostenlos starten →